48% of respiratory patient groups report representing patient interests to regulators, with almost half (47%) participating in Health Technology Assessment (HTA) and reimbursement reviews. 21% advocate for products to be included in reimbursement lists or national formularies.
48% of respondents from Respiratory conditions ‘Regularly’ or ‘Sometimes’ represent patient interests to drug regulators
Patient groups representing each Respiratory conditions sub-type
71 patient groups across 9 sub-types
interactions
We provide public comment to the Pharmaceutical Benefits Advisory Committee [PBAC] for the reimbursement of medicines relating to asthma, including some vaccines.
We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma.
National respiratory patient group, Australia
interactions
Patient Group Evidence submissions to Canada's Drug Agency (CADTH [Canadian Agency for Drugs and Technologies in Health]), INESSS [National Institute of Excellence in Health and Social Services] and BC [British Columbia] Pharmacare.
Patient Group Evidence submissions to Canada's Drug Agency (CADTH), INESSS and BC Pharmacare.
National respiratory patient group, Canada
actions & advocacy
We are actively campaigning for the amendment or abolition of Nota 99 [Nota 99 is the Italian Medicines Agency (AIFA) reimbursement guideline for Chronic Obstructive Pulmonary Disease (COPD) maintenance therapies. It regulates the prescription of inhalers, ensuring appropriate diagnosis through spirometry while detailing which treatments GPs can initiate or repeat]. We are also campaigning for vaccination against Respiratory Syncytial Virus (RSV).
Ci stiamo battendo per la modifica/abolizione della nota 99. Ci stiamo battendo per la vaccinazione per VRS.
National respiratory patient group, Italy
actions & advocacy
... Work with government members of parliament [UK] campaigning for better recognition of pulmonary fibrosis, additional funding for the treatment of the disease, greater support for the patients with the disease along with their families, carers and friends.
Work in conjunction with national and international organisations and charities. Work with government members of parliament campaigning for better recognition of pulmonary fibrosis, additional funding for the treatment of the disease, greater support for the patients with the disease along with their families, carers and friends.
Local respiratory patient group, UK
The percentages below highlight how the 34 patient groups interact with regulators and advocate for patient interests. As respondents may be represented in more than one area, percentages may not total 100%.
interactions
31 mentions
16 mentions
8 mentions
5 mentions
1 mention
1 mention
4 mentions
2 mentions
1 mention
1 mention
4 mentions
4 mentions
1 mention
1 mention
1 mention
1 mention
actions & advocacy
11 mentions
7 mentions
4 mentions
6 mentions
5 mentions
1 mention
3 mentions
2 mentions
1 mention
1 mention
1 mention
1 mention
1 mention
GET THE REPORT
Our research covers 2,262 patient groups representing 100 countries and 45 therapy areas. The sample report shows you the depth of analysis for a single country or therapy area. To access any other reports, please get in touch.
Visit patient-view.com to gather more information or email: Alex Wyke, alexwyke@patient-view.com
